awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36498695-6FE95821-F4B9-408D-ADD6-3BEC5CE3189A
Q36498695-6FE95821-F4B9-408D-ADD6-3BEC5CE3189A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36498695-6FE95821-F4B9-408D-ADD6-3BEC5CE3189A
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
P2860
Q36498695-6FE95821-F4B9-408D-ADD6-3BEC5CE3189A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36498695-6FE95821-F4B9-408D-ADD6-3BEC5CE3189A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
707cae95ae13ed4dca6ac4682fbcb4409860bf40
P2860
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.